Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 ...
Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical collaboration ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
MedPage Today on MSN
New Strategies and Platforms for Gastroesophageal Cancer
Antibody-drug conjugates, T-cell engagers, CAR T-cell therapy build on recent progress ...
Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed ...
QL1706 (PD-1/CTLA-4 bispecific antibody) plus bevacizumab specific for patients with hepatocellular carcinoma combined with lung metastasis: A secondary analysis of a prospective, single-arm, phase Ib ...
A domestically developed therapy for urothelial carcinoma — a cancer affecting the lining of the urinary system that was diagnosed in more than 90,000 people in China in 2022 — can significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results